Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer–BioNTech) vaccine effectiveness against infection and disease in Qatar, where the B.1.351 (or beta) and B.1.617.2 (or delta) variants have dominated incidence and polymerase-chain-reaction testing is done on a mass scale, is unclear.

Matéria original


Vitamin D supplementation to treat SARS-CoV-2 positive patients. Evidence from meta-analysis


Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination